HOMA-IR Liver Fibrosis Predictor: Egyptian Study
Okay, here’s a breakdown of the citations from the provided text, formatted for clarity. I’ll list the number used in the text, adn then the full citation details as provided in the title attribute of the tags.
Citations:
31: Ramírez-Mejía, M. M., Jiménez-Gutiérrez, C.,Eslam,M., George, J. & Méndez-Sánchez, N. Breaking new ground: MASLD vs MAFLD – which holds the key for risk stratification?. Hepatol. Int. 18(1), 168-178 (2024).
32: Pan, Z. et al. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatol. Int. 18(3),964-972. https://doi.org/10.1007/s12072-024-10673-7 (2024).
33: Alharthi, J. et al. Loss of metabolic adaptation in lean MAFLD is driven by endotoxemia leading to epigenetic reprogramming. Metabolism 144, 155583. https://doi.org/10.1016/j.metabol.2023.155583 (2023).
34: Eslam, M., Fan, J.-G. & Mendez-Sanchez, N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. Lancet gastroenterol. Hepatol. 5(8), 713-715 (2020).
* 35: Ye,Q. et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5(8), 739-752.
Note: Citation 35 is incomplete in the provided text. The full citation is cut off.